BioMérieux's Stock Rebounds 2.71% After Hitting a Seven-Year Low at €68.05
The stock of the Lyon-based in vitro diagnostics specialist is regaining some ground this Thursday after a dismal week. Having recorded a new seven-year low at €68.05 at the start of the session, the stock has risen to €70.10, up 2.71% from the previous day's close. The rebound comes as the stock had lost more than a fifth of its value over seven sessions.
A New Historical Low Breached at the Start of the Session
BioMérieux's stock touched €68.05 early in the morning, below the previous low of €68.25 dating from 2019. Thus, the stock erased its seven-year low, extending the movement that began after the company lowered its annual targets on April 23, following a quarterly revenue decline of 3.9% to €984 million. Since this warning, the stock has lost 21% over seven sessions and 28.29% over three months. The market capitalization has fallen by 39.72% over the year. Today's rebound occurs in a Parisian market trending downward, with the CAC 40 losing 1.14% during the session at 7,980 points. Among European comparables, Sartorius Stedim Biotech is up 0.53% and Eurofins Scientific is down 0.45%.
Price Below the Lower Bollinger Band, RSI at 17
The price at €70.10 remains below the lower Bollinger band set at €77.18, indicating a pronounced oversold condition. The RSI is at 17, a level of selling pressure rarely observed. The moving averages confirm the negative underlying trend: the MM50 at €92.33 and the MM200 at €107.43 are significantly above the current price, with gaps of approximately 31.7% and 53.3% respectively. The support threshold identified at €70.95 was breached at the opening, with the price now just below it. On the calendar, the next official milestone is the publication of the semi-annual results for 2026 scheduled for July 28, followed by the third quarter revenue on November 8.
